2015
DOI: 10.1097/nci.0000000000000113
|View full text |Cite
|
Sign up to set email alerts
|

Current Technology to Maximize Cardiac Resynchronization Therapy Benefit for Patients With Symptomatic Heart Failure

Abstract: The incidence of heart failure (HF) continues to increase, affecting millions of people in the United States each year. Cardiac resynchronization therapy (CRT) has been used and studied for patients with symptomatic HF for more than 20 years. The purpose of this article is to review technologies and developments to help maximize CRT for patients with symptomatic HF. Although most interventions to optimize CRT are physician directed, nurses also have an important role in the care and education of patients with … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2016
2016
2022
2022

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 79 publications
0
1
0
Order By: Relevance
“…CRT has the potential to improve heart failure symptoms, reduce hospital admissions, and improve the survival and functional capacity. The mechanisms of benefits from CRT include improved left ventricular remodeling resulting in reduced left ventricular size and increased ejection fraction, as well as mitigation of mitral regurgitation ( 5 , 13 ). With the advancement of retrograde coronary sinus cannulation technology, delivery systems and dedicated left ventricular lead technology, the fully transvenous route has become the first-line approach for CRT ( 14 ).…”
Section: Discussionmentioning
confidence: 99%
“…CRT has the potential to improve heart failure symptoms, reduce hospital admissions, and improve the survival and functional capacity. The mechanisms of benefits from CRT include improved left ventricular remodeling resulting in reduced left ventricular size and increased ejection fraction, as well as mitigation of mitral regurgitation ( 5 , 13 ). With the advancement of retrograde coronary sinus cannulation technology, delivery systems and dedicated left ventricular lead technology, the fully transvenous route has become the first-line approach for CRT ( 14 ).…”
Section: Discussionmentioning
confidence: 99%